95 results
6-K
EX-10.1
IPA
ImmunoPrecise Antibodies Ltd
23 Feb 24
Current report (foreign)
5:29pm
as necessary to permit preparation of financial statements in conformity with IFRS and to maintain accountability for assets; (iii) access to assets … , access, misappropriation or modification except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse
424B5
IPA
ImmunoPrecise Antibodies Ltd
23 Feb 24
Prospectus supplement for primary offering
5:26pm
unauthorized access into information systems;
prospective investors' ability to enforce civil liabilities;
the Company's status as a foreign private … experience failures of its laboratory facilities;
any contamination in animal populations;
any unauthorized access into information systems
424B5
IPA
ImmunoPrecise Antibodies Ltd
7 Dec 23
Prospectus supplement for primary offering
4:53pm
contamination in animal populations;
any unauthorized access into information systems;
prospective investors' ability to enforce civil liabilities
6-K
EX-10.1
IPA
ImmunoPrecise Antibodies Ltd
6 Dec 23
Current report (foreign)
5:19pm
preparation of financial statements in conformity with IFRS and to maintain asset accountability; (iii) access to assets is permitted only in accordance … of IT Systems, Confidential Data, and Personal Data and to the protection of such IT Systems, Confidential Data, and Personal Data from unauthorized use, access
424B5
IPA
ImmunoPrecise Antibodies Ltd
5 Dec 23
Prospectus supplement for primary offering
4:02pm
experience failures of its laboratory facilities;
any contamination in animal populations;
any unauthorized access into information systems … failures of its laboratory facilities;
any contamination in animal populations;
any unauthorized access into information systems;
prospective
6-K
EX-99.1
lvug 3hn90tx24sbmu5z
20 Oct 23
Current report (foreign)
2:56pm
6-K
EX-99.1
0a50dnvx95h
25 Sep 23
Current report (foreign)
4:46pm
6-K
EX-10.1
tsh 7poww820x
15 Aug 23
Current report (foreign)
5:50pm
424B5
gmkg1ytyq ox
15 Aug 23
Prospectus supplement for primary offering
5:47pm
6-K
EX-99.1
lum5ijukm7m6j29x
14 Jul 23
Immunoprecise Antibodies LTD. 6-K
8:10am
F-3
EX-4.3
0idxxxv
10 Jul 23
Shelf registration (foreign)
7:04pm
F-3
f4w2yi
10 Jul 23
Shelf registration (foreign)
7:04pm
40-F
EX-99.3
fe3x3 0et
10 Jul 23
Annual report (Canada)
4:32pm
40-F
EX-99.1
zbw9wer8
10 Jul 23
Annual report (Canada)
4:32pm
6-K
EX-99.1
o4xz4yuo
15 Dec 22
Current report (foreign)
8:00am
6-K
EX-99.1
th3lx
8 Dec 22
Immunoprecise Antibodies LTD. 6-K
8:05am
6-K
EX-99.2
qi23d0us63 yiobv
17 Nov 22
Current report (foreign)
9:36am
6-K
EX-99.1
0gwmwekvkyp
17 Oct 22
Annual General and Special Meeting
7:07am
6-K
EX-99.1
9xtn870k6xdhm
12 Oct 22
Immunoprecise Antibodies LTD. 6-K
8:09am
6-K
EX-99.1
fjea3 6hjxwm0d
14 Sep 22
Current report (foreign)
8:31am